Product #


Biochem/physiol Actions

Add to Cart

B3811 B-9430 trifluoroacetate salt ≥98% (HPLC) B-9430 was developed by Gera at the Stewart laboratory1 and is a stable, potent, and long lasting Bradykinin (BK) antagonist, a candidate anti-inflammatory drug. B-9430 shows potency at bradykinin B2 (pA2 = 8.6) and B1 receptors (pA2 = 7.3). Bradykinin is an important growth factor for small-cell lung cancer (SCLC) and prostate cancer (PC). BK receptors are expressed on almost all lung cancer cell lines and on many PC cells. B-9430 is very resistant to kinases and thus shows a very long action in vivo. This peptide is unique among bradykinin antagonists in that it is active after oral administration.
B3259 Bradykinin acetate salt powder, ≥98% (HPLC) Bradykinin is a pro-inflammatory peptide that acts through G-protein-coupled receptors. It activates sphingolipid metabolism. Fibroblasts treated with bradykinin produce a rapid and important increase in ceramide which is followed by a transient rise in sphingosine content. The peptide also increases ceramide cellular content by rapidly mobilizing neutral glycolipids. Bradykinin plays an important role in the regulation of fluid and electrolyte balance, smooth muscle contraction, vasodilation and capillary permeability. The bradykinin potentiators, which possess no bradykinin activity themselves, enhance the activity of bradykinin.
B1542 [Lys-des-Arg9]-Bradykinin ≥95% (HPLC) Bradykinin B1 receptor agonist.
[Des-Arg10]-kallidin is a bradykinin B1 receptor agonist. It strongly upregulates the B1 receptor and is blocked by a specific protein kinase C inhibitor. The upregulation is correlated with the induction of transcription factor nuclear factor κB (NF-κB).
B6929 Lys-(des-Arg9, Leu8)-Bradykinin trifluoroacetate salt ≥95% B1 bradykinin receptor antagonist.
B5181 7-Methoxycoumarin-4-acetyl [Ala7-(2,4-Dinitrophenyl)Lys9]-Bradykinin trifluoroacetate salt >94% (HPLC)  
B1401 Bradykinin Fragment 1-5 ≥97% (HPLC) The bradykinin (BK) fragment (1-5) (RPPGF) is among the most stable of naturally occurring metabolites. It may be used as a marker for BK production in vivo. It is known that an intact Arg residue in the C-terminus is required for biological activities. BK 1-5 is the minimal peptide that inhibited α-thrombin-induced platelet aggregation and secretion and calcium mobilization. It also prevented α-thrombin from cleaving the thrombin receptor peptide, NATLDPRSFLLR, between arginine and serine. Such antithrombin activities of BK 1-5 may contribute to the cardioprotective nature of kinins.
B1901 Bradykinin Fragment 2-9 ≥97% (HPLC) The des-arginine-1 bradykinin (BK) peptide (2-9) has no detectable contractile activity, inhibits ACE (angiotensin converting enzyme) and potentiates BK.
B1680 Bradyzide di(trifluoroacetate) salt hydrate ≥98% Potent, orally active, non-peptide B2 bradykinin receptor antagonist.
H157 HOE 140 ≥94% B2 bradykinin receptors are present in the sensory neurons. Activation of B2 receptor by bradykinin is associated with pro-inflammatory, pain producing and cardiovascular responses. HOE-140 is a selective B2 bradykinin receptor antagonist. Presence of HOE-140 suppresses the effects of bradykinin and has been shown to have anti-hyperalgesic response, particularly towards inflammatory pain.
K3628 Kininogen, low molecular weight from human plasma ≥95% (SDS-PAGE), lyophilized powder LMW kininogen is a major extracellular cysteine proteinase inhibitor. Tissue kallikrein releases bradykinin, a potent bronchoconstrictor and vasoactive agent, from both HMW and LMY kininogen.
R9032 R-715 TFA salt ≥95% (HPLC) Novel, selective, metabolically stable B1 bradykinin receptor antagonist.